Abstract
Background: Heterogeneous conduction with areas of slow conduction has been shown to be the electrophysiologic substrate responsible for AF vulnerability in a canine model of chronic mitral regurgitation (MR). ZP 123 is a hexapeptide that augments gap junction conductance, improving cell coupling. We studied its effects on this animal model and in control animals to test the hypothesis that improvement in atrial conduction would decrease the vulnerability to AF.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
